Kwenzekeni
Insilico Medicine's Alex Zhavoronkov believes China and AI can deliver the drug industry's next breakthrough. The company is running a Phase 3 trial in China for its AI-discovered drug rentosertib, which is for idiopathic pulmonary fibrosis. Insilico used AI to identify the disease target and develop the molecule to treat it. The company has also launched LongevityBench, a test of large language models' grasp of aging biology.
U-Alex Zhavoronkov we-Insilico Medicine ukholelwa ukuthi i-China ne-AI zingaletha impumelelo elandelayo embonini yezidakamizwa.
The company is running a Phase 3 trial in China for its AI-discovered drug rentosertib, which is for idiopathic pulmonary fibrosis.
Insilico used AI to identify the disease target and develop the molecule to treat it.
The company has also launched LongevityBench, a test of large language models' grasp of aging biology.
Insilico's strategy of using Chinese resources and talent to develop products for the Chinese market could be a key factor in its success.
Imininingwane yomthombo: fortune.com ↗
Kungani kubalulekile
Insilico Medicine's success in China and its use of AI to develop drugs could be a game-changer for the pharmaceutical industry. The company's AI-discovered drug rentosertib is in Phase 3 trials, and its LongevityBench test could help improve the understanding of aging biology. Insilico's strategy of using Chinese resources and talent to develop products for the Chinese market could also be a key factor in its success.
Insilico Medicine's success in China and its use of AI to develop drugs could be a game-changer for the pharmaceutical industry.
The company's AI-discovered drug rentosertib is in Phase 3 trials, and its LongevityBench test could help improve the understanding of aging biology.
Insilico's strategy of using Chinese resources and talent to develop products for the Chinese market could also be a key factor in its success.
The company's use of AI could help improve the understanding of aging biology and lead to the development of new treatments.
Insilico's success could lead to a shift in the way drugs are developed and marketed.
I-Interactive Mechanism: Indlela Esebenza Ngayo Ngempela
Hlola ubuchwepheshe obuyisisekelo ngemuva kwalokhu kuthuthukiswa ngokuhlanganyela.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
Ongakubuka ngokulandelayo
Insilico Medicine's progress in China and its use of AI to develop drugs will be closely watched by the pharmaceutical industry. The company's success could lead to a shift in the way drugs are developed and marketed, and its use of AI could help improve the understanding of aging biology.
Insilico Medicine's progress in China and its use of AI to develop drugs will be closely watched by the pharmaceutical industry.
The company's success could lead to a shift in the way drugs are developed and marketed.
Insilico's use of AI could help improve the understanding of aging biology and lead to the development of new treatments.
The company's strategy of using Chinese resources and talent to develop products for the Chinese market could be a key factor in its success.
Insilico's success could help address the issue of longevity inequality.